Adaptive Biotechnologies Corporation IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Adaptive Biotechnologies Corporation | ADPT - NASDAQ |
$15.00-$17.00 | $20.00 | $39.01 | 15 million | 6/27/2019 |
| Goldman Sachs & Co., J.P. Morgan, BofA Merrill Lynch | ||||||
Co-Manager(s): Cowen, Guggenheim, William Blair, BTIG | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-05-30 Terms Added 2019-06-17 Amended Terms 2019-06-26 | ||||||
Adaptive Biotechnologies Corporation Quote & Chart - Click for current quote - ADPT
IPO Boutique aggregates information on public companies and private companies, such as "ADPT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Adaptive Biotechnologies Corporation (adapted from Adaptive Biotechnologies Corporation prospectus):
They are advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ADPT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.